Narin Arunakul, MD
Interventional Cardiology · Branson, MONPI 1659355477
Payments from drug & device makers
Across 567 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- E.r. Squibb & Sons, L.L.C.$997
- AstraZeneca$809
- Boston Scientific$734
- Johnson & Johnson$614
- Amgen$522
- plus $3K from 30 others
What the payments were for
- Consulting fees$1,57513%
- Travel & lodging$1551%
- Food & beverage$10,31386%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 203 | $5,440 |
| E.r. Squibb & Sons, L.L.C. | 57 | $997 |
| AstraZeneca | 41 | $809 |
| Boston Scientific | 34 | $734 |
| Johnson & Johnson | 42 | $614 |
| Amgen | 38 | $522 |
| Novartis | 24 | $386 |
| Abiomed | 10 | $336 |
| Philips North America LLC | 6 | $313 |
| Pfizer | 18 | $303 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $301 |
| Boehringer Ingelheim | 17 | $289 |
| Merck | 11 | $168 |
| Lexicon Pharmaceuticals, Inc. | 4 | $88 |
| Actelion Pharmaceuticals US, Inc. | 4 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $74 |
| Novo Nordisk | 4 | $65 |
| Chiesi USA, Inc. | 3 | $50 |
| Bayer | 3 | $48 |
| Preventice Services, LLC | 3 | $46 |
| Heartflow, Inc. | 2 | $39 |
| Cardiovascular Systems Inc. | 3 | $34 |
| United Therapeutics Corporation | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Baxter Healthcare | 1 | $28 |
| Sanofi | 1 | $28 |
| Aegerion Pharmaceuticals, Inc. | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Elutia, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allure CRT Pacemaker$1,575
- Assurity Pacemaker$423
- Confirm Rx$370
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$137
- CVX-300$135
- AVEIR$116
- AMPLATZER Occluders$107
- Impella$103
How this compares
$12,048 in reported general payments places this provider in the 45th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 365 | $314,588 |
| FarxigaDapagliflozin Propanediol | 187 | $183,282 |
| EntrestoSacubitril/Valsartan | 121 | $123,049 |
| XareltoRivaroxaban | 121 | $120,203 |
| OzempicSemaglutide | 41 | $44,146 |
| JardianceEmpagliflozin | 33 | $33,477 |
| VerquvoVericiguat | 28 | $28,931 |
| Repatha SureclickEvolocumab | 28 | $24,591 |
| BrilintaTicagrelor | 35 | $22,490 |
| Repatha SyringeEvolocumab | 23 | $14,796 |
| Metoprolol Succinate | 407 | $5,318 |
| Icosapent Ethyl | 13 | $3,605 |
| Spironolactone | 286 | $2,458 |
| Nebivolol Hcl | 42 | $2,354 |
| Potassium Chloride | 176 | $1,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $303 | $314,588365 claims |
| AstraZenecaFarxiga, Brilinta | $809 | $205,772222 claims |
| NovartisEntresto | $386 | $123,049121 claims |
| Johnson & JohnsonXarelto | $614 | $120,203121 claims |
| Novo NordiskOzempic | $65 | $44,14641 claims |
| Boehringer IngelheimJardiance | $289 | $33,47733 claims |
| MerckVerquvo | $168 | $28,93128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Branson
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.